Literature DB >> 18579181

Clinical predictors of recurrent venous thromboembolism: a single institute experience in Korea.

Tae Min Kim1, Jin Soo Kim, Sae Won Han, Yong Sang Hong, Inho Kim, Jongwon Ha, Sang Joon Kim, Jin Wook Chung, Jae Hyung Park, Dongsoon Lee, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim, Sung-Soo Yoon.   

Abstract

INTRODUCTION: Racial disparities in incidence rate as well as risk factors for venous thromboembolism (VTE) exist between Asian and Western populations. Moreover, predictors for recurrent VTE were not identified in Asians. Thus, this study was undertaken to investigate risk factors for recurrent VTE events in Korean people.
MATERIALS AND METHODS: Three hundred-three patients newly diagnosed as VTE were enrolled from Seoul National University Hospital. Recurrence rate based on risk factors for VTE were investigated. Cumulative incidence of recurrent VTE was calculated by the Kaplan and Meier method. Independent predictors for VTE were determined using Cox proportional hazards model.
RESULTS: After a median follow-up of 44 months, 24 (8%) of 303 patients relapsed for a total observation time of 1,217 patient-year. Cumulative incidences of recurrent VTE were 3% at 1 year, 10% at 5 years, and 18% at 8 years. Independent predictors for recurrent VTE were presence of residual thrombosis (hazard ratio [HR]=3.1, 95% confidence interval [CI] 1.0-9.3; p=0.044), antiphospholipid syndrome (APS) (HR=4.3, 95% CI 1.0-19.0; p=0.052), and age 50 years or younger (HR=2.5, 95% CI 1.0-6.6; p=0.053) by multivariate analysis. Residual thrombosis and APS remained predictive of recurrence by the anticoagulation-period stratified analysis.
CONCLUSIONS: In contrast to Western populations, Korean patients with VTE had the lower recurrent rate. Extended anticoagulation is necessary for Korean patients with residual thrombosis or APS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579181     DOI: 10.1016/j.thromres.2008.05.009

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Preliminary Investigations Showing Venous Thromboembolism Recurrence in Patients with Residual Venous Obstruction in Singaporean Population.

Authors:  Ashish Anil Sule; Chaozer Er; Claudia Y X Chong; Han Xin Chin; Tay Jam Chin
Journal:  Int J Angiol       Date:  2017-06-15

Review 2.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

3.  Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study.

Authors:  Bruna M Mazetto; Fernanda L A Orsi; Sandra A F Silveira; Luis F Bittar; Mariane M C Flores-Nascimento; Kiara C S Zapponi; Marina P Colella; Erich V de Paula; Joyce M Annichino-Bizzacchi
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

Review 4.  The role of ethnicity, age and gender in venous thromboembolism.

Authors:  Martina Montagnana; Emmanuel J Favaloro; Massimo Franchini; Gian Cesare Guidi; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 5.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 6.  Pathophysiological Aspects of Aging in Venous Thromboembolism: An Update.

Authors:  Dimitra Akrivou; Garifallia Perlepe; Paraskevi Kirgou; Konstantinos I Gourgoulianis; Foteini Malli
Journal:  Medicina (Kaunas)       Date:  2022-08-10       Impact factor: 2.948

7.  Predictors of Recurrent Venous Thromboembolism after Pulmonary Embolism in Korea.

Authors:  Yang Ki Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2019-10

8.  Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction.

Authors:  Michael Nagler; Hugo Ten Cate; Martin H Prins; Arina J Ten Cate-Hoek
Journal:  Res Pract Thromb Haemost       Date:  2018-02-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.